Nearly One-Third Of Prostate Cancer Patient Struggle With Medication: QLife Japan Survey
This article was originally published in PharmAsia News
Nearly one-third of Japanese prostate cancer patients are not happy with their medication while 72.3% are taking more than one drug, according to a recent survey by hospital and pharmaceutical search company QLife.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.